DOCSLIB.ORG

Oomipramine Administered During the Luteal Phase Reduces the Symptoms of Premenstrual Syndrome: a Placebo-Controlled Trial Charlotta Sundblad, M.D., Marina A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Oomipramine Administered During the Luteal Phase Reduces the Symptoms of Premenstrual Syndrome: a Placebo-Controlled Trial Charlotta Sundblad, M.D., Marina A NtUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO. 2 133 Oomipramine Administered during the Luteal Phase Reduces the Symptoms of Premenstrual Syndrome: A Placebo-Controlled Trial Charlotta Sundblad, M.D., Marina A. Hedberg, M.D., and Elias Eriksson, M.D., Ph.D. II.previous controlled trial we have shown that registered daily using a visual analogue scale) were pmntTIstrual irritability and depressed mood significantly reduced during treatment; in the placebo t,mnenstrual syndrome) can be effectively reduced by group, this symptom reduction was about 45%, whereas ...doses of the potent (but nonselective) serotonin in the clomipramine group it was greater than 70%. The nptakeinhi bitor clomipramine taken each day of the mean premenstrual ratings of irritability and depressed f/tIIStrualcycle. The present study was undertaken to mood during the three treatment cycles were significantly GIIfIine to what extent intermittent administration of lower in the clomipramine group than in the placebo dDmipramine, during the luteal phase only, is also group. Also with respect to the rating of global Iftdiveagainst premenstrual complaints. Twenty-nine improvement, the result obtained with clomipramine was ..dtpressed women displaying severe premenstrual significantly better than that obtained with placebo. The iriMbility and/or depressed mood and fulfilling the study confirms the previously reported effectiveness of DSM·/ll·R criteria of late luteal phase dysphoric disorder low doses of clomipramine in the treatment of IrIr treateddaily from the day of ovulation until the premenstrual syndrome and demonstrates that the time .nof the menstruation either with clomipramine (25 lag between onset of medication and clinical effect is � 7Smg) (n = 15) or with placebo (n = 14) for three shorter when clomipramine is used for premenstrual III/StCUtive menstrual cycles; another nine subjects (seven syndrome than when it is used for depression, panic • cIomipramine, two on placebo) dropped out during disorder, or obsessive compulsive disorder. lIJIment. In both treatment groups self-rated [Neuropsychopharmacology 9:133-145, 1993J rmnmstrual irritability and depressed mood (as III WORDS: Premenstrual syndrome; Late luteal phase The cardinal symptoms of the premenstrual syndrome .".oTicdisorder; Clomipramine; Antidepressant; (PMS), or late luteal phase dysphoric disorder (LLPDD), �oninre uptake inhibitor are irritability and depressed mood; in addition, ten­ sion, increased carbohydrate craving, sleep distur­ bance, and a sense of bloating are common complaints. For fulhllment of the diagnosis, the symptoms should fIumthe Department of Pharmacology (CS, EE), and the Depart­ start regularly around ovulation or during the two _01Psychiatry and Neurochemistry (MAH), University of G6te­ ....Sweden weeks preceding the menstrual bleeding and terminate Addresscorrespondence to: Elias Eriksson, M.D., Ph.D., Depart­ within a few days after the onset of menstruation (Frank _01Pharm acology, University of G6teborg, Medicinaregatan 7, 1931; Halbreich et a1. 1982; American Psychiatric As­ S413Giiteborg, 'Xl Sweden. laivedDecember 10, 1992; revised April 27, 1993; accepted May sociation 1985). 5,1993. Most women of fertile age experience mild premen- 11993Amer ican College of Neuropsychopharmacology Nished by Elsevier Science Publishing Co., Inc. • Avenue of the Americas, New York, NY 10010 0893-133X/93/$6.00 134 C. Sundblad et al. NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.1 strual complaints (Reid 1985; Andersch et al. 1986; Chi­ menstruation as reported by the patient duringthe inter, hal 1987); needless to say, a majority of these women view. In addition, the criteria of LLPDD in DSM-III·R are capable of mastering their symptoms without medi­ (American Psychiatric Association 1985) should be cation. However, several independent studies indicate fulhlled. Exclusion criteria were: 1) previous or ongoing that as much as 10% of all menstruating women have psychiatric illness (apart from major depressive disor· premenstrual complaints of such severity that they der or dysthymic disorder), 2) ongoing major depres· would like to medicate to reduce them (Reid 1985; An­ sive disorder or dysthymic disorder (as defInedusing dersch et al. 1986; Chihal 1987). DSM-III-R and by means of the Montgomery-Asberg In a recent open study (Eriksson et al. 1990), fol­ Depression Scale), 3) major depressive disorder or dys­ lowed by a confIrmative placebo-controlled trial (Sund­ thymic disorder less than 2 years from the time of the blad et al. 1992), we have shown that daily intake interview, 4) ongoing medication for somatic or psy· throughout the menstrual cycle of low doses of the an­ chiatric illness, 5) ongoing medication with oral con· tidepressant clomipramine very effectively reduces traceptives, 6) ongoing alcohol abuse, 7) ongoing so­ premenstrual sadness and irritability in nondepressed matic illness, 8) irregular menstruations, 9) ongoing or women suffering from LLPDD. It was hypothesized planned pregnancy, 10) less than 18 years of age, and that the impressive effect of clomipramine in reducing 11) previous treatment with antidepressants for premen­ premenstrual complaints was mainly due to the sero­ strual complaints. Informed consent was obtained from tonin reuptake inhibiting effect of the drug. all participants. In spite of the comparatively low doses used in Before starting medication, all participants per· these studies (25 to 75 mg per day), side effects of the formed daily rating with respect to the possible occur· treatment were not uncommon. For this reason, sev­ rence of irritability, depressed mood, tension, increased eral of the participating women expressed the opinion appetite and/or carbohydrate craving, breast tender· that intermittent administration of the drug during the ness, and bloating, respectively, for two subsequent premenstrual phase only would be more attractive than menstrual cycles using a visual analogue scale (VAS) a medication given also during the symptom-free follic­ (0 to 100 mm; 0 mm = no complaints, 100 mm = maxi· ular phase. As judged by the clinical profIle of clomi­ mal complaints). Subjects not displaying the following pramine when used for the treatment of depression, evidence of menstrually related changes during both panic disorder (Modigh et al. 1992), and obsessive­ reference cycles were excluded from the study. 1) More compulsive disorder (OCD) (Katz et al. 1990), one than a 100% increase in either irritability or depressed would not expect such a noncontinuous medication to mood (or both) during the premenstrual phase (calcu· be effective; thus, in most trials, clomipramine, like lated as the mean rating of the 5 days before the 1st day other monoamine reuptake inhibitors, requires at least of menstruation) as compared to the postmenstru� 2 to 3 weeks of treatment to exert marked clinical effects. phase (calculated as the mean rating of days 6 to 1001 Hence, we were surprisedwhen a small group of women the cycle; cycle day 1 = the 1st day of menstruation). with severe premenstrual complaints during an open 2) Mean premenstrual rating of irritability or depressed pilot trial indeed reported a marked effectof clomipra­ mood exceeding 20 mm. In addition, some participants mine also when the drug was taken in the luteal phase were excluded during the course of the two reference only (Sundblad and Eriksson,unpublished fInding).To cycles due to other reasons (such as pregnancy and on· investigate whether this response is indeed related to set of depression). the pharmacodynamics of clomipramine or is merely Immediately after the second reference cycle, the a placebo effect,the present controlled trial of intermit­ participants fulfIlling the inclusion criteria were ran· tent administration of clomipramine in severe LLPDD domized either to the clomipramine or to the placelxJ was undertaken. group. For practical reasons a number of participants were included in the randomization before having com­ pleted the rating of the second reference cycle; some SUBJECTS AND METHODS of these turned out to display an unsatisfactory symp­ tom rating during the reference cycles and were hence Recruitment and Inclusion Criteria excluded in spite of the fact that they had been part01 Women with premenstrual irritability and/or depressed the randomization. mood were recruited by means of a newspaper adver­ tisement followed by a brief telephone interview and Medication a subsequent, extensive, structured interview. The pri­ mary inclusion criteria were severe irritability and/or After the 2 months of symptom rating, medication depressed mood starting regularly around ovulation or started for patients not excluded due to unsatisfactoli during the 2 weeks preceding the menstrual bleeding rating (or other reasons) during the reference cycles. and terminating within a few days after the onset of Tablets containing placebo and clomipramine, respec' SEL"ROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO. 2 Clomipramine in the Premenstrual Syndrome 135 li¥eIy,were identical in shape, size, and color, and both ing, breast tenderness, and bloating) as during the two piients and investigators were unaware of whether the pretreatment reference cycles. In addition, symptoms filient was given placebo or clomipramine until the were rated also during one additional drug-free refer­ lludywas completed. Treatment started at the esti­ ence cycle after the three cycles of medication were com­ liltedtime of ovulation (14 days before expected men­ pleted. To obtain a global assessment of possible
Load more

Recommended publications
  • 22 Psychiatric Medications for Monitoring in Primary Care
    22 Psychiatric Medications for Monitoring in Primary Care Medication Warnings, Precautions, and Adverse Events Comments Class: SSRI Fluvoxamine Boxed Warnings: Suicidality Used much less than SSRIs in the group of eight Indications: Warnings and Precautions: Similar to other SSRIs medications for prescribing, probably because it has no Adult: OCD Adverse Events: Similar to other SSRIs FDA indication for MDD or any anxiety disorder. Still Child/Adolescent: OCD (10-17 years) somewhat popular as a medication for OCD. Uses: Anxiety, OCD Monitoring: Same as other SSRIs Citalopram Boxed Warning: Suicidality. Escitalopram, one of the SSRIs in the group of Indications: Warnings and Precautions: Similar to other SSRIs medications for prescribing, is an active metabolite of Adult: MDD Adverse Events: Similar to other SSRIs citalopram. Escitalopram reportedly has fewer AEs and Child/Adolescent: None less interaction with hepatic metabolic enzymes than Uses: Anxiety, MDD, OCD citalopram but is otherwise essentially identical. Citalopram offers no advantage other than price, as Monitoring: Same as other SSRIs escitalopram is branded until 2012. Paroxetine Boxed Warnings: Suicidality. Paroxetine used much less than the SSRIs for Indications: Warnings and Precautions: Similar to other SSRIs prescribing, probably because of its nonlinear kinetics. Adult: MDD, OCD, Panic Disorder, Generalized Anxiety Adverse Events: Similar to other SSRIs A study of children and adolescents showed doubling Disorder, Social Anxiety Disorder, Posttraumatic Stress Disorder the dose of paroxetine from 10 mg/day to 20 mg/day Child/Adolescent: None resulted in a 7-fold increase in blood levels (Findling et Uses: Anxiety, MDD, OCD al, 1999). Thus, once metabolic enzymes are saturated, paroxetine levels can increase dramatically with dose Monitoring: Same as other SSRIs increases and decrease dramatically with dose decreases, sometimes leading to adverse events.
    [Show full text]
  • Drugs That Can Cause Delirium (Anticholinergic / Toxic Metabolites)
    Drugs that can Cause Delirium (anticholinergic / toxic metabolites) Deliriants (drugs causing delirium) Prescription drugs . Central acting agents – Sedative hypnotics (e.g., benzodiazepines) – Anticonvulsants (e.g., barbiturates) – Antiparkinsonian agents (e.g., benztropine, trihexyphenidyl) . Analgesics – Narcotics (NB. meperidine*) – Non-steroidal anti-inflammatory drugs* . Antihistamines (first generation, e.g., hydroxyzine) . Gastrointestinal agents – Antispasmodics – H2-blockers* . Antinauseants – Scopolamine – Dimenhydrinate . Antibiotics – Fluoroquinolones* . Psychotropic medications – Tricyclic antidepressants – Lithium* . Cardiac medications – Antiarrhythmics – Digitalis* – Antihypertensives (b-blockers, methyldopa) . Miscellaneous – Skeletal muscle relaxants – Steroids Over the counter medications and complementary/alternative medications . Antihistamines (NB. first generation) – diphenhydramine, chlorpheniramine). Antinauseants – dimenhydrinate, scopolamine . Liquid medications containing alcohol . Mandrake . Henbane . Jimson weed . Atropa belladonna extract * Requires adjustment in renal impairment. From: K Alagiakrishnan, C A Wiens. (2004). An approach to drug induced delirium in the elderly. Postgrad Med J, 80, 388–393. Delirium in the Older Person: A Medical Emergency. Island Health www.viha.ca/mhas/resources/delirium/ Drugs that can cause delirium. Reviewed: 8-2014 Some commonly used medications with moderate to high anticholinergic properties and alternative suggestions Type of medication Alternatives with less deliriogenic
    [Show full text]
  • Headshop Highs & Lows
    HeadshopHeadshop HighsHighs && LowsLows AA PresentationPresentation byby DrDr DesDes CorriganCorrigan HeadshopsHeadshops A.K.A.A.K.A. ““SmartSmart ShopsShops””,, ““HempHemp ShopsShops””,, ““HemporiaHemporia”” oror ““GrowshopsGrowshops”” RetailRetail oror OnlineOnline OutletsOutlets sellingselling PsychoactivePsychoactive Plants,Plants, ‘‘LegalLegal’’ && ““HerbalHerbal”” HighsHighs asas wellwell asas DrugDrug ParaphernaliaParaphernalia includingincluding CannabisCannabis growinggrowing equipment.equipment. Headshops supply Cannabis Paraphernalia HeadshopsHeadshops && SkunkSkunk--typetype (( HighHigh Strength)Strength) CannabisCannabis 1.1. SaleSale ofof SkunkSkunk--typetype seedsseeds 2.2. AdviceAdvice onon SinsemillaSinsemilla TechniqueTechnique 3.3. SaleSale ofof HydroponicsHydroponics && IntenseIntense LightingLighting .. CannabisCannabis PotencyPotency expressedexpressed asas %% THCTHC ContentContent ¾¾ IrelandIreland ¾¾ HerbHerb 6%6% HashHash 4%4% ¾¾ UKUK ¾¾ HerbHerb** 1212--18%18% HashHash 3.4%3.4% ¾¾ NetherlandsNetherlands ¾¾ HerbHerb** 20%20% HashHash 37%37% * Skunk-type SkunkSkunk--TypeType CannabisCannabis && PsychosisPsychosis ¾¾ComparedCompared toto HashHash smokingsmoking controlscontrols ¾¾ SkunkSkunk useuse -- 77 xx riskrisk ¾¾ DailyDaily SkunkSkunk useuse -- 1212 xx riskrisk ¾¾ DiDi FortiForti etet alal .. Br.Br. J.J. PsychiatryPsychiatry 20092009 CannabinoidsCannabinoids ¾¾ PhytoCannabinoidsPhytoCannabinoids-- onlyonly inin CannabisCannabis plantsplants ¾¾ EndocannabinoidsEndocannabinoids –– naturallynaturally occurringoccurring
    [Show full text]
  • The Psychoactive Effects of Psychiatric Medication: the Elephant in the Room
    Journal of Psychoactive Drugs, 45 (5), 409–415, 2013 Published with license by Taylor & Francis ISSN: 0279-1072 print / 2159-9777 online DOI: 10.1080/02791072.2013.845328 The Psychoactive Effects of Psychiatric Medication: The Elephant in the Room Joanna Moncrieff, M.B.B.S.a; David Cohenb & Sally Porterc Abstract —The psychoactive effects of psychiatric medications have been obscured by the presump- tion that these medications have disease-specific actions. Exploiting the parallels with the psychoactive effects and uses of recreational substances helps to highlight the psychoactive properties of psychi- atric medications and their impact on people with psychiatric problems. We discuss how psychoactive effects produced by different drugs prescribed in psychiatric practice might modify various disturb- ing and distressing symptoms, and we also consider the costs of these psychoactive effects on the mental well-being of the user. We examine the issue of dependence, and the need for support for peo- ple wishing to withdraw from psychiatric medication. We consider how the reality of psychoactive effects undermines the idea that psychiatric drugs work by targeting underlying disease processes, since psychoactive effects can themselves directly modify mental and behavioral symptoms and thus affect the results of placebo-controlled trials. These effects and their impact also raise questions about the validity and importance of modern diagnosis systems. Extensive research is needed to clarify the range of acute and longer-term mental, behavioral, and physical effects induced by psychiatric drugs, both during and after consumption and withdrawal, to enable users and prescribers to exploit their psychoactive effects judiciously in a safe and more informed manner.
    [Show full text]
  • Adverse Effects of First-Line Pharmacologic Treatments of Major Depression in Older Adults
    Draft Comparative Effectiveness Review Number xx Adverse Effects of First-line Pharmacologic Treatments of Major Depression in Older Adults Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov This information is distributed solely for the purposes of predissemination peer review. It has not been formally disseminated by the Agency for Healthcare Research and Quality. The findings are subject to change based on the literature identified in the interim and peer-review/public comments and should not be referenced as definitive. It does not represent and should not be construed to represent an Agency for Healthcare Research and Quality or Department of Health and Human Services (AHRQ) determination or policy. Contract No. 290-2015-00012I Prepared by: Will be included in the final report Investigators: Will be included in the final report AHRQ Publication No. xx-EHCxxx <Month, Year> ii Purpose of the Review To assess adverse events of first-line antidepressants in the treatment of major depressive disorder in adults 65 years or older. Key Messages • Acute treatment (<12 weeks) with o Serotonin norepinephrine reuptake inhibitors (SNRIs) (duloxetine, venlafaxine), but not selective serotonin reuptake inhibitors (SSRIs) (escitalopram, fluoxetine) led to a greater number of adverse events compared with placebo. o SSRIs (citalopram, escitalopram and fluoxetine) and SNRIs (duloxetine and venlafaxine) led to a greater number of patients withdrawing from studies due to adverse events compared with placebo o Details of the contributing adverse events in RCTs were rarely reported to more clearly characterize what adverse events to expect.
    [Show full text]
  • Frequently Asked Questions About Antidepressant Medications
    Frequently Asked Questions about Antidepressant Medications How do antidepressant medications work? Antidepressants affect the balance of chemicals in the brain that affect mood. These are called neurotransmitters. However, research has not clarified exactly how antidepressants work. Are antidepressants addictive? No. They are not habit – forming and do not produce a “high.” Once you reach a dose that works for you, you do not require ever increasing doses to maintain the beneficial effect. Will I get better if I take an antidepressant? Antidepressant medications are proven to improve mood for most people with moderate or severe depression. Combining antidepressant medication with psychotherapy is even more effective. For mild depression, many people may improve with supportive counseling and active follow up from their primary care physician. If mild depression persists, then antidepressant medication and / or psychotherapy are usually effective. For all levels of depression, healthy lifestyle is important. This include eating healthy foods, sleeping and exercising regularly, engaging in pleasurable activities, using stress reduction techniques, and sharing your thoughts and concerns with supportive friends or family. How long will it take for the antidepressant medication to work? People usually start to feel better two to four weeks after starting an antidepressant. Sleep and appetite may improve first, but it may take longer for your mood and energy to improve. If your depression is not improved after a few weeks, your doctor may suggest adding psychotherapy (if you are not already doing this), increasing the dose or switching to another medication. Are there any side effects from antidepressants? Side effects are usually mild.
    [Show full text]
  • Depression and Anxiety Pharmacological Treatment in General Practice
    THEME Mental health Depression and anxiety Pharmacological treatment in general practice BACKGROUND Depression and anxiety are common presentations in general practice and medications are one of the key treatment strategies. OBJECTIVE This article provides an overview of important practical issues to consider when prescribing medications for anxiety and depression. Steven Ellen MBBS, MMed(Psych), DISCUSSION MD, FRANZCP, is Head, Key questions for the general practitioner to consider are: Consultation-Liaison • Are medications the best option? Psychiatry, The Alfred Hospital, • Which is the best medication for this patient? Melbourne, Victoria. s.ellen@ alfred.org.au • What are the practical aspects of prescribing this medication? • What is the next step if it doesn’t work? Rob Selzer MBBS, PhD, FRACP, FRANZCP, is Consultant Psychiatrist, Primary Mental Health & Early General practitioners are the main providers symptom of other disorders such as physical illness. From Intervention Team, The Alfred Hospital, Melbourne, Victoria. of treatment for anxiety and depression in our a prescribing point of view, separating depression from community and medications are often prescribed anxiety and vice versa, is less crucial as they often occur Trevor Norman as part of the treatment plan. The BEACH study together, and the pharmacological first line for both is often BSc, PhD, is Associate Professor, Department of (Bettering the Evaluation and Care of Health Program)1 the same (an antidepressant). Psychiatry, University of showed that GPs treat psychological problems at a Following diagnosis, the next important issue is the Melbourne, Austin Hospital, rate of 11.5 per 100 encounters, and medications are patient’s attitude to medication. What are their preferences Heidelberg, Victoria.
    [Show full text]
  • Appendix D: Switching Antidepressants Switching Antidepressants Can Be Accomplished by the Following Strategies: 1
    Appendix D: Switching Antidepressants Switching antidepressants can be accomplished by the following strategies: 1. Direct switch: stop the first antidepressant abruptly and start new antidepressant the next day. 2. Taper & switch immediately: gradually taper the first antidepressant, then start the new antidepressant immediately after discontinuation. 3. Taper & switch after a washout: gradually withdraw the first antidepressant, then start the new antidepressant after a washout period. 4. Cross-tapering: taper the first antidepressant (usually over 1-2 week or longer), and build up the dose of the new antidepressant simultaneously. The following table is intended for general guidance only. Whichever strategy is used, patients should be closely monitored for symptoms and adverse events. The duration of tapering should be determined individually for each patient. Physicians should balance the risk of discontinuation symptoms versus risk of delay in new treatment. The washout period is mostly dependent on the t1/2 of the first drug. To Switching From ➞ SSRIs (except fluoxetine) Fluoxetine SNRIs NDRI (bupropion) NaSSA (mirtazapine) RIMA (moclobemide) TCA Taper & stop, then start new Taper & stop, then start Taper & stop5 (or to low Taper & stop5 (or to low Taper & stop5 (or to Taper & stop, wait 1 week, Cross-taper cautiously with SSRIs (except ➞ SSRI at a low dose1,† fluoxetine at low dose dose),1 then start low dose dose),2 then start bupropion. low dose),1 then start then start moclobemide.1,5 very low dose TCA.1,3,5,‡,§ fluoxetine) (10 mg daily)1,† SNRI & very slowly.1,3,5,† mirtazapine cautiously. Stop fluoxetine, wait 4-7 Stop fluoxetine, wait 4-7 Stop fluoxetine, wait 4-7 Stop fluoxetine, wait 4-7 Stop fluoxetine, wait 5 Stop fluoxetine, wait 4-7 Fluoxetine* ➞ days.
    [Show full text]
  • Antidepressant- and Anxiolytic Effects of the Novel Melatonin Agonist Neu-P11 in Rodent Models
    Acta Pharmacologica Sinica (2010) 31: 775–783 npg © 2010 CPS and SIMM All rights reserved 1671-4083/10 $32.00 www.nature.com/aps Original Article Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models Shao-wen TIAN1, #, *, Moshe LAUDON2, #, Li HAN1, 3, Jun GAO1, Fu-lian HUANG1, Yu-feng YANG1, Hai-feng DENG1 1Department of Physiology, Medical School, University of South China, Hengyang 421001, China; 2Neurim Pharmaceuticals Ltd, Tel- Aviv, Israel; 3Department of Physiology, Changsha Medical University, Changsha 410219, China Aim: To investigate the potential antidepressant and anxiolytic effects of Neu-P11, a novel melatonin agonist, in two models of depression in rats and a model of anxiety in mice. Methods: In the learned helplessness test (LH), Neu-P11 or melatonin (25–100 mg/kg, ip) was administered to rats 2 h before the beginning of the dark phase once a day for 5 days and the number of escape failures and intertrial crossings during the test phase were recorded. In the forced swimming test (FST), rats received a single or repeated administration of Neu-P11 (25–100 mg/kg, ip). The total period of immobility during the test phase was assessed. In the elevated plus-maze test (EPM), mice were treated with Neu- P11 (25–100 mg/kg, ip) or melatonin in the morning or in the evening and tested 2 h later. The percentage of time spent in the open arms and the open arms entries were assessed. Results: In the LH test, Neu-P11 but not melatonin significantly decreased the escape deficit and had no effect on the intertrial cross- ings.
    [Show full text]
  • At-A-Glance: Psychotropic Drug Information for Children and Adolescents
    At-A-Glance: Psychotropic Drug Information for Children and Adolescents Pediatric Dosage/ Drug Generic FDA Approval Serum Level Name Age/Indication when applicable Warnings and Precautions/Black Box Warnings Combination Antipsychotic/Antidepressant fluoxetine & 18 and older N/A: Pediatric Black Box Warning for fluoxetine/olanzapine olanzapine dosing is currently combination formula (marketed as Symbyax): Usage unavailable or not increased the risk of suicidal thinking and behaviors in applicable for this children and adolescents with major depressive disorder drug. and other psychiatric disorders. Other precautions for fluoxetine/olanzapine combination: Possibly unsafe during lactation. Avoid abrupt withdrawal. Antipsychotic Medications *Precautions which apply to all atypical or second generation antipsychotics (SGA): Neuroleptic Malignant Syndrome/Tardive Dyskinesia/ Hyperglycemia/ Diabetes Mellitus/ Weight Gain/ Akathisia/Dyslipidemia †Precautions which apply to all typical or first generation antipsychotics (FGA): Extrapyramidal symptoms/Tardive Dyskinesia aripiprazole * (SGA) 10 and older for 2-10 mg/kg/day Black Box Warning for aripiprazole: Not approved for bipolar disorder, depression in under age 18. Increased risk of suicidal manic, or mixed thinking and behavior in short-term studies in children episodes; 13 to 17 and adolescents with major depressive disorder and for schizophrenia other psychiatric conditions. and bipolar; 6 to 17 for irritability associated with autistic disorder asenapine* 18 and older N/A Black Box Warning for asenapine: Not approved for dementia-related psychosis. Increased mortality risk for elderly dementia patients due to cardiovascular or infectious events. chlorpromazine† 18 and older 0.25 mg/kg tid Other precautions for chlorpromazine: May alter cardiac (FGA) conduction; sedation; Neuroleptic Malignant Syndrome; weight gain. Use caution with renal disease, seizure disorders, and respiratory disease and in acute illness.
    [Show full text]
  • Medication Guide Antidepressant Medicines, Depression and Other Serious Mental Illnesses, and Suicidal Thoughts Or Actions
    Medication Guide Antidepressant Medicines, Depression and other Serious Mental Illnesses, and Suicidal Thoughts or Actions Read the Medication Guide that comes with you or your family member’s antidepressant medicine. This Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines. Talk to your, or your family member’s, healthcare provider about: • all risks and benefits of treatment with antidepressant medicines • all treatment choices for depression or other serious mental illness What is the most important information I should know about antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions? 1. Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment. 2. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called manic-depressive illness) or suicidal thoughts or actions. 3. How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member? • Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed. • Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. • Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.
    [Show full text]
  • Drug-Related Mortality: Postmortem Findings in Clark County, Nevada for 2005
    UNLV Retrospective Theses & Dissertations 1-1-2007 Drug-related mortality: Postmortem findings in Clark County, Nevada for 2005 Melanie Lee Gulmatico University of Nevada, Las Vegas Follow this and additional works at: https://digitalscholarship.unlv.edu/rtds Repository Citation Gulmatico, Melanie Lee, "Drug-related mortality: Postmortem findings in Clark County, Nevada for 2005" (2007). UNLV Retrospective Theses & Dissertations. 2110. http://dx.doi.org/10.25669/jq0h-bm62 This Thesis is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV with permission from the rights-holder(s). You are free to use this Thesis in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Thesis has been accepted for inclusion in UNLV Retrospective Theses & Dissertations by an authorized administrator of Digital Scholarship@UNLV. For more information, please contact [email protected]. DRUG-RELATED MORTALITY: POSTMORTEM FINDINGS IN CLARK COUNTY, NEVADA FOR 2005 By Melanie Lee Gulmatico Bachelor of Science University of Nevada, Las Vegas 2005 A thesis submitted in partial fulfillment of the requirements for the Master of Public Health Degree School of Public Health Division of Health Sciences Graduate College University of Nevada, Las Vegas May 2007 Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. UMI Number: 1443758 INFORMATION TO USERS The quality of this reproduction is dependent upon the quality of the copy submitted.
    [Show full text]